TNP 2500
Alternative Names: MDR-TB; TNP2500Latest Information Update: 27 Dec 2022
Price :
$50 *
At a glance
- Originator Cumbre Pharmaceuticals
- Developer TenNor Therapeutics
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections; Tuberculosis
Most Recent Events
- 27 Dec 2022 Discontinued for Bacterial infections in China (unspecified route) (TenNor Therapeutics website, December 2022)
- 28 Oct 2020 No recent reports of development identified for research development in Bacterial-infections in China
- 14 Sep 2016 TenNor Therapeutics has patent protection for dual-acting molecules, including TNP 2500 in USA (TenNor Therapeutics website; September 2016)